id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-325052-7vlxa0i7	Williamson, E. D.	Vaccines for emerging pathogens: prospects for licensure	2019-04-11		.txt	text/plain	6218	267	42	However, vaccines for pathogens which cause severe, but occasional, disease outbreaks in endemic pockets have suffered from a lack of commercial incentive for development to a clinical standard, encompassing Phase III clinical trials for efficacy. While approval of vaccines for diseases caused by such pathogens would Clinical and Experimental Immunology REvIEw ARtIClE Series Editor: E Diane williamson make a significant impact on disease outbreaks, taking niche vaccines into clinical development, including Phase III clinical trials for efficacy, requires a large investment in time and money. An alternative is to develop such vaccines to request US Emergency Use Authorization (EUA), or an alternative status in the United States, Canada and European Union (EU) making use of a considerable number of alternative regulatory mechanisms that are available prior to licensing, so that the products are deployable at the first indications of a disease outbreak.	./cache/cord-325052-7vlxa0i7.txt	./txt/cord-325052-7vlxa0i7.txt